CN1966002A - Pharmaceutical composition for treating tinea and complication thereof - Google Patents
Pharmaceutical composition for treating tinea and complication thereof Download PDFInfo
- Publication number
- CN1966002A CN1966002A CN 200610114632 CN200610114632A CN1966002A CN 1966002 A CN1966002 A CN 1966002A CN 200610114632 CN200610114632 CN 200610114632 CN 200610114632 A CN200610114632 A CN 200610114632A CN 1966002 A CN1966002 A CN 1966002A
- Authority
- CN
- China
- Prior art keywords
- complication
- treatment
- tinea
- pharmaceutical composition
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002474 Tinea Diseases 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 241000130764 Tinea Species 0.000 title abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims description 28
- 241000893966 Trichophyton verrucosum Species 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- -1 inuncts Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract description 2
- 240000007890 Leonurus cardiaca Species 0.000 abstract description 2
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 241001313857 Bletilla striata Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 244000223014 Syzygium aromaticum Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 201000004647 tinea pedis Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 206010005913 Body tinea Diseases 0.000 description 4
- 206010067197 Tinea manuum Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000003875 tinea corporis Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed is a pharmaceutical composition for treating tinea and its complications, which comprises Chinese medicinal herbs including cortex pseudolaricis, clove, bletilla striata, motherwort and licorice root, and has the advantages of low cost, short course of treatment, higher curing rate, and low recurrence rate.
Description
One, technical field: the present invention relates to medical technical field, in particular for the pharmaceutical composition of treatment ringworm and complication thereof.
Two, background technology: said composition comprises Chinese medicines such as Cortex Pseudolaricis, Flos Caryophylli, the Pseudobulbus Bletillae (Rhizoma Bletillae), Herba Leonuri, Radix Glycyrrhizae.
Cortex Pseudolaricis belongs to detoxifcation parasite killing dampness removing to stop itchin class medicine, has good parasite killing and treats tinea, removing dampness itching-relieving action, and external can be controlled the card of eczema, scabies and various skin pruritus; Especially be longer than the treatment tinea, specially control various tinea diseases such as tinea corporis, tinea capitis, the tinea manuum, tinea pedis.To 10 kinds of common pathomycetes of China, the tinea bacterium of particularly causing a disease all has the anti-effect that presses down, when 0.1-1mg/ml to oidium schoenleinii, acrothesium floccosum, rust tinea bacterium, microsporon gypseum, read ball bacterium etc. in vain bactericidal action arranged; Because of this product oral toxicity is bigger, do not take orally clinically, only do external, in the external process, do not see the clinical report of toxic reaction up till now as yet.
The Genus Syringa Wen Han class medicine that activates yang cures mainly tinea manus and pedis, tinea corporis and cruris, tuberculosis of skin, xerosis cutis, and tubercule bacillus is had the complete inhibition effect, and dermatophytes and other pathogenic bacterium are had certain inhibitory or killing effect.Flos Caryophylli is one of common food flavouring agent.
The Pseudobulbus Bletillae (Rhizoma Bletillae) belongs to hemostasis analgesic therapy class medicine, has the effect of astringing to arrest bleeding, detumescence and promoting granulation, diseases such as treatment of ulcer swells and ache, rhagadia manus et pedis, chilblain, tuberculosis of skin.
Mother wort promoting blood circulation, removing blood stasis and relieving pain class medicine has the effect of clearing heat, releasing toxin, removing swelling, is used for the treatment of diseases such as stasis, amenorrhea, dredge the meridian passage, edema and pain, can be used for sore and toxic again, diseases such as itchy skin eruption, i.e. oral administration, but also external application, washout.
Glycyrrhiza invigorating the spleen and benefiting QI class medicine has coordinating the actions of various ingredients in a prescription, separates the effect of hundred poison of drug, and the poisoning due to some drugs, food, interior metabolism product and the bacteriotoxin thereof is all had certain Detoxication; Modern study: Radix Glycyrrhizae has adrenocortical hormone sample function, coordinates substance metabolism, and enhancing body is to the adaptive capacity of adverse circumstances, and has effects such as antiulcer, antiinflammatory, antitumor, antitussive, blood fat reducing; Oral administration, but also external.
It is known as the compositions of active princlple that application contains Cortex Pseudolaricis, Flos Caryophylli, the Pseudobulbus Bletillae (Rhizoma Bletillae), Herba Leonuri, Radix Glycyrrhizae, but with Cortex Pseudolaricis, Flos Caryophylli, the Pseudobulbus Bletillae (Rhizoma Bletillae), Herba Leonuri, Radix Glycyrrhizae compatibility as the compositions of treatment ringworm and complication thereof report as yet.
Ringworm is due to pathomycete infects, the sick skin hyperplasia plumpness of decreasing of clinical manifestation, violent pruritus, so occur swelling and ache, drying chaps incrustation desquamation or complication such as wellability eczema and infection suppurates.As untimely treatment, can decrease because of a certain local disease and infect other position of health, as being passed by tinea pedis is the tinea manuum, tinea manus and pedis passes and is tinea unguium, though threat to life safety does not influence routine work, studying and living because of pruritus swells and ache, and has reduced quality of life and health level, the primary disease prevalence is high and rise treatment back relapse rate height year by year.
The improvement of current antifungal drug research toxic and side effect, remain major subjects, use the hormons medication to the different antagonism of external antifungal medicament active meeting generation degree, abusing antibiotic makes pathomycete produce certain Drug resistance again, it is many and complicated that treatment by Chinese herbs ringworm and complication thereof have active ingredient, and interact, play a role from multipath, too many levels, many target spots, many-side, and cure rate height, relapse rate are low.But the seen on the market treatment ringworm and the medicine of complication have, and a lot of prescriptions are numerous and diverse, the medicine of similar effect repeats in a prescription, cause efficacy exertion bad, the waste resource, what also have can not take into account complication, maybe can not fully recover and prolonged the course of treatment, what also have cures the symptoms, not the disease, and causes after patient's medication just sx and does not heal for a long time; And expense is all somewhat expensive.
Three, summary of the invention: for the shortcoming and defect of the medicine that overcomes existing treatment ringworm and complication thereof, this is bright to provide a kind of compositions, and said composition is principal agent with the Cortex Pseudolaricis, and is all effective at various ringworms treatments; Flos Caryophylli is inferior, and Cortex Pseudolaricis treatment ringworm is played the complementary effect of addition; The effect of the complication that treatment causes by ringworm is played in Pseudobulbus Bletillae (Rhizoma Bletillae) astringing to arrest bleeding, detumescence and promoting granulation analgesic therapy; The Herba Leonuri promoting blood circulation, removing blood stasis and relieving pain, dredge the meridian passage, clearing heat, releasing toxin, removing swelling makes the drug effect of respectively distinguishing the flavor of be able to effective performance, and the effect of treatment itchy skin eruption is also arranged; Radix Glycyrrhizae plays coordinating the actions of various ingredients in a prescription, separates hundred poison of drug, separates patient's internal metabolism toxin and bacteriotoxic effect, and its adrenocortical hormone sample function works to promote the performance drug effect to other medicines, and antagonism can not occur, and pathogenic bacterium are developed immunity to drugs.
Because the result of broad research, the inventor has found that Cortex Pseudolaricis, Flos Caryophylli, the Pseudobulbus Bletillae (Rhizoma Bletillae), Herba Leonuri, the novel combination of Radix Glycyrrhizae, this novel combination have synergism for treatment ringworm and complication thereof, this synergism makes all medicines give full play to effect, shortened the course of treatment, cure rate improves, relapse rate descends, and cost does not improve, and is convenient to clinical using and does not have toxicity.
The invention provides the pharmaceutical composition that is used for the treatment of ringworm and complication thereof, it comprises Cortex Pseudolaricis, Flos Caryophylli, the Pseudobulbus Bletillae (Rhizoma Bletillae), Herba Leonuri, Radix Glycyrrhizae as active princlple; Respectively distinguishing the flavor of in the compositions, each medical material market is all available at home for medical material, and its extract also has the professional production manufacturer production.
Respectively distinguishing the flavor of Chinese medicine among the present invention can be with its extract as raw material, by the present invention's Chinese medicine extract effective dose of respectively distinguishing the flavor of, in whole crude drug is by weight ratio: Cortex Pseudolaricis 5-30g; Flos Caryophylli 3-20g; Pseudobulbus Bletillae (Rhizoma Bletillae) 3-20g; Herba Leonuri 3-20g; Radix Glycyrrhizae 5-30g.
Compositions of the present invention can be pressed the dispenser of series preparation form, for example: powder, lotion, unguentum, stick agent, inuncts, mix and prepare with known drug carrier, adjuvant and additive, also can make tablet, powder earlier, add relevant carriers again when using and use, be prepared by usual way.Wherein inuncts and lotion available water and/or vinegar and/or 50-95% ethanol is as carrier, the also available acetic acid of described vinegar, salicylic acid, benzoic acid etc.
Advantage of the present invention is that this compositions has notable therapeutic effect to treatment ringworm and complication thereof, and the compositions each component has good synergism, thereby reduces cost of drugs, cure rate improves, relapse rate descends, and no incompatibility has no adverse reaction and toxic reaction.Sufficient raw.
Four, the specific embodiment:
Relatively tabulate below with reference to embodiment and clinical implementation effect and to be described in detail the present invention:
Embodiment 1: prescription: (by whole crude drug)
Cortex Pseudolaricis 20g;
Flos Caryophylli 10g;
Pseudobulbus Bletillae (Rhizoma Bletillae) 10g;
Herba Leonuri 15g;
Radix Glycyrrhizae 25g;
To add medicine to adds clear water 1500ml immersion 1 hour, and filtered through gauze is used in slow fire boiling 20 minutes, and when treating that temperature is reduced to 40 ℃ of left and right sides, bubble is suffered from hands, the foot of tinea, each 20 minutes, every day 2 times.Filter the reuse of heating next day.
Embodiment 2: fill a prescription with embodiment 1:
Each medicine of prescription is immersed in 48 hours after-filtration among the 75% ethanol 500ml, makes tincture, wipe the affected part every day outward 3 times.
Embodiment 3: fill a prescription with embodiment 1:
Each medicine of prescription is immersed among the 75% ethanol 200ml 48 hours adds the 300ml mature vinegar again, make externally applied liniment after the filtration, every day 3 times.
Embodiment 4: fill a prescription with embodiment 1:
Each medicine of prescription after purifying, with relevant externally used paste carrier (as animal oil, vegetable oil, vaseline etc.) 80g uniform mixing, is made unguentum, and every day, coating was 5 times.
Embodiment 5:
(1) Therapeutic Method: earlier by the administrated method dispenser of embodiment 1, dry suffer from behind hands, the foot again by
The method dispenser of embodiment 3.
(2) clinical data: control patient's 50 examples altogether, tinea pedis 43 examples wherein, hands, tinea pedis 3 examples, tinea corporis 4 examples, wherein male 32 examples, women 18 examples, minimum 12 years old of age, maximum 59 years old, average 26 years old; The course of disease is the longest 2 years, and is the shortest 2 months, person's 6 examples that have the suppurative infection concurrently, and all patients all do not have allergies; Most of patients once used all kinds of cream (water) medicine, PIYANPING and hormones ointment to be coated with outward.
(3) criterion of therapeutical effect: recovery from illness; Clinical symptoms and local erythra all disappear, and microscopy fungus feminine gender is embrocated with 0.9% normal saline in the affected part; Produce effects: clinical symptoms and skin lesion obviously improvement reach 70%, and the smear for microscopic examination fungal filament reduces; Take a turn for the better: clinical symptoms and skin lesion make moderate progress and reach 50%, and mycology is checked positive; Invalid: clinical symptoms, sign and fungus are checked no significant change.
3.2 therapeutic effect: see attached list 1:
Subordinate list 1:50 example hands, foot, tinea corporis observation of curative effect statistical table:
| Patient's number | Recovery from illness | Produce effects | Take a turn for the better | Invalid | Total effective rate % | Cure rate % |
| 50 people | 41 | 7 | 1 | 1 | 98％ | 82％ |
6 routine suppurative infection persons all fully recover.
The enforcement of this compositions contrast clinical report in the past has notable therapeutic effect as can be seen from the subordinate list of embodiment 5.
Claims (1)
1, a kind of pharmaceutical composition that is used for the treatment of ringworm and complication thereof is characterized in that it is made by weight ratio by following raw materials according:
Cortex Pseudolaricis 5---30g;
Flos Caryophylli 3---20g;
The Pseudobulbus Bletillae (Rhizoma Bletillae) 3---20g;
Herba Leonuri 3---20g;
Radix Glycyrrhizae 3---20g;
Make unguentum, inuncts, lotion, powder, stick agent by known pharmaceutical methods, make sheet or powder earlier after also can will medicine purifying, add relevant carriers again when using and use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101146326A CN100488547C (en) | 2006-11-20 | 2006-11-20 | Pharmaceutical composition for treating tinea and complication thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101146326A CN100488547C (en) | 2006-11-20 | 2006-11-20 | Pharmaceutical composition for treating tinea and complication thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1966002A true CN1966002A (en) | 2007-05-23 |
| CN100488547C CN100488547C (en) | 2009-05-20 |
Family
ID=38075095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101146326A Expired - Fee Related CN100488547C (en) | 2006-11-20 | 2006-11-20 | Pharmaceutical composition for treating tinea and complication thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100488547C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106620455A (en) * | 2017-03-05 | 2017-05-10 | 李子义 | Medicine for treating tinea capitis and preparation method of medicine |
| CN108283663A (en) * | 2018-03-07 | 2018-07-17 | 马睿 | A kind of composition with prevention ringworm of the foot effect |
-
2006
- 2006-11-20 CN CNB2006101146326A patent/CN100488547C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106620455A (en) * | 2017-03-05 | 2017-05-10 | 李子义 | Medicine for treating tinea capitis and preparation method of medicine |
| CN108283663A (en) * | 2018-03-07 | 2018-07-17 | 马睿 | A kind of composition with prevention ringworm of the foot effect |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100488547C (en) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
| CN1739638A (en) | Medicine for treating dermatosis and its prepn | |
| CN102302661B (en) | One treats dermopathic Chinese medicine composition | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN101703651A (en) | Medicament for treating diabetic gangrene | |
| CN101934032B (en) | Chinese medicinal compound external preparation for treating diabetes and preparation method and application thereof | |
| CN100488547C (en) | Pharmaceutical composition for treating tinea and complication thereof | |
| CN1695682A (en) | External use preparation for treating rheumatisma and bone injuries | |
| CN1289119C (en) | Chinese medicine sanjieruxiao ointment and its preparation method | |
| CN1895489A (en) | Externally-applied medicinef or treating psoriasis | |
| CN1895593A (en) | Medicine for treating acne and its preparation | |
| CN101961455A (en) | Traditional Chinese medicine for treating chronic colitis disease | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN1296084C (en) | Externally applied medicine for treating chronic dermatopathy | |
| CN103520427A (en) | Traditional Chinese medicine for treating body-resistance-weak and pathogen-strong type chronic osteomyelitis and preparation method thereof | |
| CN102764421B (en) | Pressure ulcer ointment | |
| CN116832125B (en) | Traditional Chinese medicine composition, preparation method and application thereof | |
| CN101983681A (en) | Medicament for treating abnormal leucorrhea | |
| CN1240378C (en) | Externally applied preparation for removing dampness and relieving osteodynia | |
| CN114788854A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101049491A (en) | Application of stomachic pill with cyperus and amomum | |
| CN1726941A (en) | Medicine for treating chronic hemorrhoids | |
| CN101785832B (en) | Traditional Chinese medicine preparation and preparation method thereof for skin disease treatment | |
| Cho et al. | Panax noto-ginseng Enhances Wound Healing Efficiency and Quality on Diabetic Rats | |
| CN102430067B (en) | Method for preparing medicament for treating hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING GUANWUZHOU INSTITUTE OF BIOLOGICAL SCIENC Free format text: FORMER OWNER: ZHU WEI Effective date: 20080822 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080822 Address after: Room 916, building 1203, southeast district, Haidian District Academy of Sciences, Beijing, Zhongguancun: 100086 Applicant after: Beijing Guanwuzhou Biological Scientific Institute Address before: Room 2, room 916, building 1203, southeast district, Beijing Academy of Sciences, Zhongguancun, China: 100086 Applicant before: Zhu Wei |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Beijing Liqianqiu Technology Development Co., Ltd. Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090520 Termination date: 20121120 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |